These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 38111571)

  • 1. Heterogeneity of tertiary lymphoid structures in cancer.
    You X; Koop K; Weigert A
    Front Immunol; 2023; 14():1286850. PubMed ID: 38111571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients.
    Houel A; Foloppe J; Dieu-Nosjean MC
    Semin Immunol; 2023 Sep; 69():101796. PubMed ID: 37356421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
    N J; J T; Sl N; Gt B
    Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation.
    Domblides C; Rochefort J; Riffard C; Panouillot M; Lescaille G; Teillaud JL; Mateo V; Dieu-Nosjean MC
    Front Immunol; 2021; 12():698604. PubMed ID: 34276690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
    Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
    Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.
    Jia W; Zhang T; Yao Q; Li J; Nie Y; Lei X; Mao Z; Wang Y; Shi W; Song W
    Front Immunol; 2022; 13():870458. PubMed ID: 35844587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
    Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy.
    Langouo Fontsa M; Padonou F; Willard-Gallo K
    Expert Rev Clin Immunol; 2024 Aug; 20(8):839-847. PubMed ID: 39007892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy.
    Bao X; Lin X; Xie M; Yao J; Song J; Ma X; Zhang X; Zhang Y; Liu Y; Han W; Liang Y; Hu H; Xu L; Xue X
    Front Immunol; 2024; 15():1413067. PubMed ID: 39026670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.
    Zhang Y; Xu M; Ren Y; Ba Y; Liu S; Zuo A; Xu H; Weng S; Han X; Liu Z
    Mol Cancer; 2024 Apr; 23(1):75. PubMed ID: 38582847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer.
    Vaccaro A; van de Walle T; Ramachandran M; Essand M; Dimberg A
    Front Immunol; 2023; 14():1275378. PubMed ID: 37954592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tertiary lymphoid structure formation: cooperation between inflammation and antigenicity.
    Khanal S; Wieland A; Gunderson AJ
    Front Immunol; 2023; 14():1267654. PubMed ID: 37809103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response.
    Zhang Q; Wu S
    Front Immunol; 2022; 13():1063711. PubMed ID: 36713409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures.
    Omotesho QA; Escamilla A; Pérez-Ruiz E; Frecha CA; Rueda-Domínguez A; Barragán I
    Front Immunol; 2024; 15():1348156. PubMed ID: 38333212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
    Sofopoulos M; Fortis SP; Vaxevanis CK; Sotiriadou NN; Arnogiannaki N; Ardavanis A; Vlachodimitropoulos D; Perez SA; Baxevanis CN
    Cancer Immunol Immunother; 2019 Nov; 68(11):1733-1745. PubMed ID: 31598757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
    Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
    Front Immunol; 2021; 12():629519. PubMed ID: 33746966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
    Liu Z; Meng X; Tang X; Zou W; He Y
    Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.